RP Educational Trust Group of Institutions, India
*Corresponding author: Gaurav Agarwal, Faculty of Pharmacy, RP Educational Trust Group of Institutions, Karnal (Haryana), 132001, India, Email: email@example.com
Submission: December 12, 2017; Published: February 23, 2018
ISSN: 2578-0247Volume1 Issue2
The aim of present is to develop & evaluate Sustained release matrix tablet of Repaglinide. Repaglinide is an effective antihyperglycemic. But owing to its shorter half life it needs frequent administration. In present study, an attempt has been made to develop Sustained release matrix tablet of Repaglinide thereby reducing its frequency of administration & other dose related side effects. Various grades of HPMC (K4M, 100M & 15M) were used as hydrophilic matrix polymer. Croscarmellose was used as swelling agent. Total 9 formulations were prepared in trial batches. The formulation was evaluated for various pre compression & post compression parameters. All the formulations showed compliance with the pharmacopoeial standards. On the basis of evaluated parameters formulation F9 was considered to be the best one. Formulation F9 containing polymer HPMC showed 99.15% invitro drug release profile. The release data for formulation F9 was fitted to various mathematical models like zero order, first order, Krosmeyer Peppas & Higuchi model. It was observed that drug follows zero order & Higuchi model.
Keywords: Repaglinide; Sustained Release Matrix; HPMC (K4M, K100M, K15M); Croscarmellose; Wet Granulation